Intellia Therapeutics (NTLA) Non Operating Income (2021 - 2026)

Intellia Therapeutics (NTLA) has 6 years of Non Operating Income data on file, last reported at $4.3 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $4.3 million, down 33.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.1 million (up 72.37% YoY), and the FY2025 annual result was $28.3 million, up 85.64% from the prior year.
• Non Operating Income rose to $4.3 million in Q1 2026 per NTLA's latest filing, from $2.9 million in the prior quarter.
• Over five years, Non Operating Income peaked at $10.2 million in Q3 2025 and troughed at -$7.9 million in Q2 2024.
• A 5-year average of $3.9 million and a median of $6.6 million in 2024 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income tumbled 2306.02% in 2022, then soared 464.03% in 2023.
• A 5-year view of Non Operating Income shows it stood at -$3.3 million in 2022, then surged by 332.86% to $7.7 million in 2023, then dropped by 2.35% to $7.5 million in 2024, then plunged by 61.27% to $2.9 million in 2025, then surged by 47.09% to $4.3 million in 2026.
• Business Quant data shows NTLA's Non Operating Income at $4.3 million in Q1 2026, $2.9 million in Q4 2025, and $10.2 million in Q3 2025.